Modality
mRNA
MOA
DLL3 ADC
Target
AuroraA
Pathway
PI3K/AKT
SCDCLL
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
Oct 2017
→ Jan 2029
Phase 3Current
NCT04322011
1,649 pts·SCD
2020-04→2029-01·Completed
NCT05032021
772 pts·SCD
2017-10→2025-05·Terminated
NCT06516141
2,291 pts·SCD
2025-01→2026-03·Active
4,712 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-0211mo agoPh3 Readout· SCD
2026-03-192w agoPh3 Readout· SCD
2029-01-092.8y awayPh3 Readout· SCD
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Termina…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2025-05-02 · 11mo ago
SCD
Ph3 Readout
2026-03-19 · 2w ago
SCD
Ph3 Readout
2029-01-09 · 2.8y away
SCD
ActiveCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04322011 | Phase 3 | SCD | Completed | 1649 | Biomarker |
| NCT05032021 | Phase 3 | SCD | Terminated | 772 | DAS28 |
| NCT06516141 | Phase 3 | SCD | Active | 2291 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| SND-4562 | Syndax | NDA/BLA | AuroraA |